Management Comment Pharmacokinetics results demonstrated CAT-1004 average plasma exposure levels consistent with those previously observed in adults at which inhibition of NF-kB was observed. Based on these results, Catabasis plans to initiate Part B of the MoveDMD trial in the first half of 2016.